LVW Advisors LLC Sells 61 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

LVW Advisors LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% in the first quarter, HoldingsChannel reports. The firm owned 2,836 shares of the medical research company’s stock after selling 61 shares during the period. LVW Advisors LLC’s holdings in Charles River Laboratories International were worth $768,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Dumont & Blake Investment Advisors LLC increased its holdings in Charles River Laboratories International by 1.4% during the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock valued at $1,196,000 after purchasing an additional 62 shares in the last quarter. Thrive Wealth Management LLC increased its holdings in Charles River Laboratories International by 11.4% during the 1st quarter. Thrive Wealth Management LLC now owns 1,076 shares of the medical research company’s stock valued at $292,000 after purchasing an additional 110 shares in the last quarter. Cardinal Capital Management increased its holdings in Charles River Laboratories International by 16.2% during the 1st quarter. Cardinal Capital Management now owns 9,822 shares of the medical research company’s stock valued at $2,661,000 after purchasing an additional 1,372 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of Charles River Laboratories International by 1,072.7% in the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after buying an additional 236 shares during the period. Finally, Riverview Trust Co acquired a new stake in shares of Charles River Laboratories International in the 1st quarter valued at $100,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on CRL shares. Mizuho started coverage on Charles River Laboratories International in a research note on Friday, June 7th. They issued a “neutral” rating and a $235.00 target price for the company. Barclays started coverage on Charles River Laboratories International in a research note on Friday. They issued an “equal weight” rating and a $230.00 target price for the company. The Goldman Sachs Group started coverage on Charles River Laboratories International in a research note on Thursday, June 6th. They issued a “buy” rating and a $290.00 target price for the company. Robert W. Baird lowered their target price on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Finally, StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $254.50.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

CRL stock opened at $203.08 on Tuesday. The business’s 50-day moving average price is $219.57 and its two-hundred day moving average price is $232.55. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The firm has a market cap of $10.46 billion, a PE ratio of 23.89, a P/E/G ratio of 1.95 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).